FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to a method based on a redundantly designed combination of data for indicating a presence or absence of aggressive prostate cancer (PCa) in an individual, comprising the steps of obtaining a biological sample from said individual; analysing biomarkers PCa and SNP, associated with PCa (SNPpc) in said biological sample; combining the data; determining correlation of said combined value with the presence or absence of aggressive PCa in said individual. Group of inventions also relates to a device for carrying out the steps of this method; a test kit for carrying out the steps of this method.
EFFECT: group of inventions provides better analysis results than using only the PSA test.
18 cl, 4 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROGNOSTIC METHOD FOR INDIVIDUALS WITH PROSTATE CANCER | 2013 |
|
RU2669809C2 |
| METHOD FOR DETECTING SOLID MALIGNANT TUMOR | 2015 |
|
RU2720148C2 |
| METHOD OF HARMONIZING ANALYSIS RESULTS | 2019 |
|
RU2817657C2 |
| SYSTEMS AND METHODS FOR IMPROVEMENT OF DIAGNOSTICS OF DISEASES, USING MEASURED ANALYTES | 2018 |
|
RU2782359C2 |
| METHODS FOR PREDICTING PROSTATE CANCER | 2016 |
|
RU2760577C2 |
| REAGENT KIT FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS | 2018 |
|
RU2735918C2 |
| URINE BIOMARKER COHORTS, GENE EXPRESSION SIGNATURES AND METHODS OF USE THEREOF | 2014 |
|
RU2668164C2 |
| THERAPEUTIC AGENTS AND USE THEREOF | 2012 |
|
RU2606773C2 |
| METHOD OF TREATING PROSTATE CANCER WITH DEGARELIX THAT IS GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST | 2009 |
|
RU2504393C2 |
| BIOMARKERS FOR PREDICTION OF INCIDENT CANCER | 2011 |
|
RU2586295C2 |
